These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10688498)

  • 1. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2000 Feb; 107(2):165-9. PubMed ID: 10688498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.
    Menon U; Talaat A; Jeyarajah AR; Rosenthal AN; MacDonald ND; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    Br J Cancer; 1999 Jul; 80(10):1644-7. PubMed ID: 10408412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.
    Gentry-Maharaj A; Burnell M; Dilley J; Ryan A; Karpinskyj C; Gunu R; Mallett S; Deeks J; Campbell S; Jacobs I; Sundar S; Menon U
    Am J Obstet Gynecol; 2020 Jan; 222(1):56.e1-56.e17. PubMed ID: 31351062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study.
    Sundar S; Agarwal R; Davenport C; Scandrett K; Johnson S; Sengupta P; Selvi-Vikram R; Kwong FL; Mallett S; Rick C; Kehoe S; Timmerman D; Bourne T; Van Calster B; Stobart H; Neal RD; Menon U; Gentry-Maharaj A; Sturdy L; Ottridge R; Deeks J;
    Lancet Oncol; 2024 Oct; 25(10):1371-1386. PubMed ID: 39362250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
    Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.
    Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T; Oi H
    Gynecol Obstet Invest; 2008; 65(2):133-8. PubMed ID: 17957102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for ovarian cancer: a pilot randomised controlled trial.
    Jacobs IJ; Skates SJ; MacDonald N; Menon U; Rosenthal AN; Davies AP; Woolas R; Jeyarajah AR; Sibley K; Lowe DG; Oram DH
    Lancet; 1999 Apr; 353(9160):1207-10. PubMed ID: 10217079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.
    Tailor A; Bourne TH; Campbell S; Okokon E; Dew T; Collins WP
    Ultrasound Obstet Gynecol; 2003 Apr; 21(4):378-85. PubMed ID: 12704748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
    Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
    Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.
    Lu KH; Skates S; Hernandez MA; Bedi D; Bevers T; Leeds L; Moore R; Granai C; Harris S; Newland W; Adeyinka O; Geffen J; Deavers MT; Sun CC; Horick N; Fritsche H; Bast RC
    Cancer; 2013 Oct; 119(19):3454-61. PubMed ID: 23983047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.
    Hensley ML; Robson ME; Kauff ND; Korytowsky B; Castiel M; Ostroff J; Hurley K; Hann LE; Colon J; Spriggs D
    Gynecol Oncol; 2003 Jun; 89(3):440-6. PubMed ID: 12798709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study.
    Funston G; Hamilton W; Abel G; Crosbie EJ; Rous B; Walter FM
    PLoS Med; 2020 Oct; 17(10):e1003295. PubMed ID: 33112854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
    Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening postmenopausal women for ovarian cancer: a systematic review.
    Fung MF; Bryson P; Johnston M; Chambers A;
    J Obstet Gynaecol Can; 2004 Aug; 26(8):717-28. PubMed ID: 15307976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of screening for ovarian cancer: a multicenter study in Japan.
    Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T
    Int J Gynecol Cancer; 2008; 18(3):414-20. PubMed ID: 17645503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study.
    Jacobs IJ; Skates S; Davies AP; Woolas RP; Jeyerajah A; Weidemann P; Sibley K; Oram DH
    BMJ; 1996 Nov; 313(7069):1355-8. PubMed ID: 8956699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.
    Menon U; Skates SJ; Lewis S; Rosenthal AN; Rufford B; Sibley K; Macdonald N; Dawnay A; Jeyarajah A; Bast RC; Oram D; Jacobs IJ
    J Clin Oncol; 2005 Nov; 23(31):7919-26. PubMed ID: 16258091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).
    Sharma A; Apostolidou S; Burnell M; Campbell S; Habib M; Gentry-Maharaj A; Amso N; Seif MW; Fletcher G; Singh N; Benjamin E; Brunell C; Turner G; Rangar R; Godfrey K; Oram D; Herod J; Williamson K; Jenkins H; Mould T; Woolas R; Murdoch J; Dobbs S; Leeson S; Cruickshank D; Fourkala EO; Ryan A; Parmar M; Jacobs I; Menon U
    Ultrasound Obstet Gynecol; 2012 Sep; 40(3):338-44. PubMed ID: 22911637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.